AnaptysBio (ANAB) announced that its board of directors has authorized a stock repurchase plan under which the company may repurchase up to $100M of the company’s outstanding common stock, par value $0.001 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio board approves spin-off of First Tracks Biotherapeutics
- AnaptysBio price target raised to $90 from $70 at UBS
- AnaptysBio: Buy Rating on Durable Jemperli Royalties and High-Impact TRAX Pipeline Upside
- AnaptysBio price target raised to $50 from $36 at Truist
- AnaptysBio price target raised to $85 from $56 at Stifel